Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States

ORLANDO, Fla., June 05, 2018 (GLOBE NEWSWIRE) via OTC PR WIRE Immune Therapeutics, Inc. (OTCQB:IMUN) ( Immune, “IMUN” or the Company ), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS is pleased to announce a modification of the Company’s 2014 exclusive licensing agreement with Cytocom, Inc., a late stage biotechnology company that specializes in T-Cell activation immunotherapies. In addition to the rights granted The post Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States appeared first on Public Wire.
http://bit.ly/2LZJIEx